Natco Pharma wins US approval for cancer drug, shares soar

Natco Pharma just scored a big win! They got the green light from the US health regulator for their generic cancer drug, Erdafitinib, available in 3 mg, 4 mg, and 5 mg doses. This drug is aimed at helping adults with tough urothelial cancer. After the news, Natco's shares jumped 3.39% to Rs 851.45 on the Bombay Stock Exchange.